BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the shares ahead of earnings. For the Cystic Fibrosis franchise, the near-term focus will be on the launch of Alyftrek following the recent approval, says the analyst, who notes the the firm’s doctor checks indicated significant interest in switching patients to Alyftrek once approved given the more convenient daily dosing.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Biotech Alert: Searches spiking for these stocks today
- Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
- Apple, Intel little changed near noon following earnings: Morning Buzz
- Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
- Early notable gainers among liquid option names on January 31st